toripalimab
junshi biosciences,coherus
['neotorch', 'toripalimab', 'nsclc', 'sclc', 'ts,perio,i', 'lcsm,(-blcsm)']
perioperative platinum-doublet +/- toripalimab in stage ii/iii nsclc cancer (neotorch study by prof. shun lu. comparable 24m efs rate with other perioperative trials based on primary analysis just stage iii patients. how it will be like with stage ii patients? #asco23 #lcsm 
Medical Oncologist, National Cancer Center Hospital, Lung Cancer Study Group @JCOG_official, Educational Committee @JSMO_official, @JLCS_OFFICIAL, @IASLC